Literature DB >> 22807617

Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948.

Wen-Sheng Huang1, Tian-Bao Wang, Yao He, Yu-Jun Chen, Shi-Long Zhong, Min Tan.   

Abstract

AIM: To investigate the gene knock-down effect by the phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA)-targeted double-stranded RNA (dsRNA) and its effect on cell proliferation and cycle distribution in SW948.
METHODS: Two PIK3CA-targeted dsRNAs were constructed and transfected into SW948 cells. Transfections were performed using lipofectamine™ 2000. The transfection effectiveness was calculated basing on the rate of fluorescence cell of SW948 at 6 h after transfection. Total messenger RNA was extracted from these cells using the RNeasy kit, and semiquantitative reverse transcription polymerase chain reaction was performed to detect the down-regulation of PIK3CA, AKT1, MYC, and CCND1 gene expression. Cells were harvested, proteins were resolved, and western blot was employed to detect the expression levels of PIK3CA, AKT1, MYC, and CCND1 gene. Cell proliferation was assessed by 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide assay and the inhibition rate was calculated. Soft agar colony formation assay was performed basing on colonies greater than 60 μm in diameter at ×100 magnification. The effect on cell cycle distribution and apoptosis was assessed by flow cytometry. All experiments were performed in triplicate.
RESULTS: Green fluorescence was observed in SW948 cell transfected with plasmid Pgenesil-1, and the transfection effectiveness was about 65%. Forty-eight hours post-transfection, mRNA expression of PIK3CA in SW948 cells was 0.51 ± 0.04 vs 0.49 ± 0.03 vs 0.92 ± 0.01 vs 0.93 ± 0.03 (P = 0.001 ) in Pgenesil-CA1, Pgenesil-CA2, negative and blank group respectively. mRNA expression of AKT1 was 0.50 ± 0.03 vs 0.48 ± 0.01 vs 0.93 ± 0.04 vs 0.92 ± 0.02 (P = 0.000) in Pgenesil-CA1, Pgenesil-CA2, negative and blank group respectively. mRNA expression of MYC was 0.49 ± 0.01 vs 0.50 ± 0.04 vs 0.90 ± 0.02 vs 0.91 ± 0.03 (P = 0.001) in the four groups respectively. mRNA expression of CCND1 was 0.45 ± 0.02 vs 0.51 ± 0.01 vs 0.96 ± 0.03 vs 0.98 ± 0.01 (P = 0.001) in the four groups respectively. The protein level of PIK3CA was 0.53 ± 0.01 vs 0.54 ± 0.02 vs 0.92 ± 0.03 vs 0.91 ± 0.02 (P = 0.001) in Pgenesil-CA1, Pgenesil-CA2, negative and blank group respectively. The protein level of AKT1 in the four groups was 0.49 ± 0.02 vs 0.55 ± 0.03 vs 0.94 ± 0.03 vs 0.95 ± 0.04, P = 0.000). The protein level of MYC in the four groups was 0.51 ± 0.03 vs 0.52 ± 0.04 vs 0.92 ± 0.02 vs 0.95 ± 0.01 (P = 0.000). The protein level of CCND1 in the four groups was 0.54 ± 0.04 vs 0.56 ± 0.03 vs 0.93 ± 0.01 vs 0.93 ± 0.03 (P = 0.000). Both Pgenesil-CA1 and Pgenesil-CA2 plasmids significantly suppressed the growth of SW948 cells when compared with the negative or blank group at 48 h after transfection (29% vs 25% vs 17% vs 14%, P = 0.001), 60 h after transfection (38% vs 34% vs 19% vs 16%, P = 0.001), and 72 h after transfection (53% vs 48% vs 20% vs 17%, P = 0.000). Numbers of colonies in negative, blank, CA1, and CA2 groups were 42 ± 4, 45 ± 5, 8 ± 2, and 10 ± 3, respectively (P = 0.000). There were more than 4.5 times colonies in the blank and negative control groups as there were in the CA1 and CA2 groups. In addition, the colonies in blank and negative control groups were also larger than those in the CA1 and CA2 groups. The percentage of cells in the CA1 and CA2 groups was significantly higher in G₀/G₁ phase, but lower in S and G₂/M phase when compared with the negative and control groups. Moreover, cell apoptosis rates in the CA1 and CA2 groups were 5.11 ± 0.32 and 4.73 ± 0.32, which were significantly higher than those in negative (0.95 ± 0.11, P = 0.000) and blank groups (0.86 ± 0.13, P = 0.001). No significant difference was found between CA1 and CA2 groups in cell cycle distribution and apoptosis.
CONCLUSION: PIK3CA-targeted short hairpin RNAs can block the phosphoinositide 3-kinase-Akt signaling pathway and inhibit cell growth, increase apoptosis, and induce cell cycle arrest in the PIK3CA-mutant colon cancer SW948 cells.

Entities:  

Keywords:  Colon cancer; Phosphoinositide-3-kinase pathway; Phosphoinositide-3-kinase, catalytic, alpha polypeptide; RNA interference

Mesh:

Substances:

Year:  2012        PMID: 22807617      PMCID: PMC3396200          DOI: 10.3748/wjg.v18.i26.3458

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.

Authors:  Guangchao Sui; Christina Soohoo; El Bachir Affar; Frédérique Gay; Yujiang Shi; William C Forrester; Yang Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA.

Authors:  Frank Czauderna; Melanie Fechtner; Hüseyin Aygün; Wolfgang Arnold; Anke Klippel; Klaus Giese; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

3.  RNA interference by expression of short hairpin RNAs suppresses bcl-xL gene expression in nasopharyngeal carcinoma cells.

Authors:  Fang Liu; Cheng-Wei He; Yue-Fei Zhang; Ke-Yuan Zhou
Journal:  Acta Pharmacol Sin       Date:  2005-02       Impact factor: 6.150

4.  Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity.

Authors:  Hai-Tao Guan; Xing-Huan Xue; Zhi-Jun Dai; Xi-Jing Wang; Ang Li; Zhao-Yin Qin
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

5.  Lipoprotein (a) serum levels in chronic cholestatic liver disease during treatment with ursodeoxycholic acid.

Authors:  U Beuers; M M Ritter; W O Richter; G Paumgartner
Journal:  Arch Intern Med       Date:  1990-07

6.  Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Authors:  Udit N Verma; Rama M Surabhi; Aurelia Schmaltieg; Carlos Becerra; Richard B Gaynor
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

7.  Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues.

Authors:  Zhao-Shan Niu; Bo-Kian Li; Mei Wang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

8.  Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.

Authors:  Wolfgang Hartmann; Boris Digon-Söntgerath; Arend Koch; Anke Waha; Elmar Endl; Indra Dani; Dorota Denkhaus; Cynthia G Goodyer; Niels Sörensen; Otmar D Wiestler; Torsten Pietsch
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

9.  Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.

Authors:  Alison M Condliffe; Keith Davidson; Karen E Anderson; Chris D Ellson; Tom Crabbe; Klaus Okkenhaug; Bart Vanhaesebroeck; Martin Turner; Louise Webb; Matthias P Wymann; Emilio Hirsch; Thomas Ruckle; Montserrat Camps; Christian Rommel; Shaun P Jackson; Edwin R Chilvers; Len R Stephens; Phillip T Hawkins
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

10.  PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

Authors:  Magdalena Cizkova; Aurélie Susini; Sophie Vacher; Géraldine Cizeron-Clairac; Catherine Andrieu; Keltouma Driouch; Emmanuelle Fourme; Rosette Lidereau; Ivan Bièche
Journal:  Breast Cancer Res       Date:  2012-02-13       Impact factor: 6.466

View more
  1 in total

1.  PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.

Authors:  R L Ross; H R McPherson; L Kettlewell; S D Shnyder; C D Hurst; O Alder; M A Knowles
Journal:  BMC Cancer       Date:  2016-07-28       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.